In the United States, the crude incidence rate (100,000 person-years [PYs]) of pulmonary NTM disease is significantly higher in the anti-TNF-exposed RA population compared with unexposed RA patients (105 vs. 19.2) and the general population (105 vs. 4.1) [21]. This evidence concerns the gene TNF and rheumatoid arthritis.